What Cergentis does

Cergentis B.V. is a Netherlands-domiciled biotechnology company that built its business around a proprietary Targeted Locus Amplification (TLA) technology platform used for genetic characterization and quality control (QC) testing of cell lines employed in biopharmaceutical manufacturing. The TLA platform enables targeted sequencing of genomic loci of interest and is positioned as a tool for assessing genetic stability of production cell lines and supporting the development of safe and effective advanced therapies, with particular emphasis on cell and gene therapy (CGT) programs.

In 2022, Cergentis was acquired by Solvias AG, a Swiss-headquartered contract research organization (CRO) with a 25-year track record serving pharmaceutical and biotech innovators. Following the acquisition, Cergentis' operations were progressively integrated into Solvias, and by 2024 the Cergentis service line is delivered under the Solvias brand while the Cergentis name and scientific team continue to be referenced for genetic QC work. Within Solvias' broader portfolio, the TLA-based offering sits alongside analytical method development and validation, cGMP drug substance and drug product testing, biosafety testing, extractables and leachables, stability testing, and impurity/contamination control services — covering the drug development journey from initial investigation through commercialization.

Cergentis operates as a B2B professional services line. Pricing is quote-based and contract-specific. The go-to-market is enterprise-led, relying on direct sales and account management, supported by industry conferences, scientific publications, and content marketing. The primary customer segments are biologics developers and companies developing cell and gene therapies; a secondary segment comprises small molecule developers using Solvias' broader analytical services. Via Solvias, the combined entity serves 700 customers worldwide, including 19 of the top 20 global pharmaceutical companies, with a workforce of 800+ (including 175+ PhD-level scientists) across Europe and the United States.

Name

Cergentis

Legal name

Cergentis B.V.

Website

https://cergentis.com

Company type

Private

Founded year

2012

Operating status

Acquired

Headcount range

11–50 employees

Short description

Cergentis B.V., now part of Solvias, provides proprietary Targeted Locus Amplification (TLA)-based genetic characterization and quality control services for cell lines used in biopharmaceutical manufacturing, primarily serving biologics and cell/gene therapy developers worldwide.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services - Biopharmaceutical Analytical Testing

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Genetic characterization services
• Cell line QC testing
• Targeted locus amplification
• Biologics analytical services
• Cell line genetic stability

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Contract Research Organization Services: CMC analytical testing services for pharmaceutical and biotech companies. Provides comprehensive analytical solutions from raw materials to drug products, including genetic quality control testing and release services.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Cergentis specializes in genetic characterization and quality control testing for cell lines used in biopharmaceutical manufacturing and advanced therapy development, using its proprietary Targeted Locus Amplification (TLA) technology platform. The company delivers comprehensive genetic stability assessment and QC services to pharmaceutical and biotech companies developing biologics, cell therapies, and gene therapies. Services are now offered through parent company Solvias as part of its broader CMC analytical services platform.

Product overview

Cergentis, now part of Solvias, offers a specialized portfolio centered on its proprietary Targeted Locus Amplification (TLA) technology platform. The company provides genetic characterization and quality control services primarily for cell lines used in biopharmaceutical and advanced therapy development. As part of Solvias' broader CMC analytical services offering, Cergentis services complement capabilities including analytical method development, cGMP testing, and biosafety testing. The TLA platform and genetic QC services form a distinct offering focused on genetic stability assessment for biologics and cell/gene therapy development.

Differentiator

Problem solved

Functional benefit

Products and services

• Genetic Quality Control Testing

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Solvias AGflagship - cergentis was acquired by solvias in 2022 to bolster biologics and cell & gene therapy capabilities. the acquisition integrates cergentis into solvias' comprehensive cmc analytical services platform.Strategic or Co-development PartnerCergentis was acquired by Solvias in 2022. This acquisition brought Cergentis' Targeted Locus Amplification (TLA) technology platform and expertise in genetic characterization and QC to Solvias. The partnership supports Solvias' strategy to provide comprehensive solutions for pharmaceutical developers from initial investigation to commercialization.

Scale indicators4 records

Expansion highlights4 records

Emerging players

• GenScript ProBio: GenScript ProBio provides cell line development, plasmid manufacturing, and analytical testing for biologics including CGT. Its analytical services for cell line genetic stability and viral clearance are a direct partial overlap with Cergentis' TLA-based QC value proposition.
• Sartorius Cell Line Development & QC: Sartorius offers analytical tools and services for cell line development, including genetic stability testing through its product portfolio. As a bioprocess supplier expanding into analytical services, Sartorius is an emerging peer with overlapping capability but narrower service orientation.

Broad incumbents

• BioReliance (MilliporeSigma / Merck KGaA): BioReliance is the legacy brand of Merck's biosafety testing and characterization services, offering cell line genetic characterization, viral clearance, and biosafety testing to pharma and CGT developers. It directly competes with Cergentis' TLA-based QC services while also offering a far broader testing portfolio under Merk's Life Sciences segment.
• Eurofins Scientific: Eurofins is a global testing services group with pharma product testing, genomics, and bioanalytical capabilities acquired through multiple bolt-ons. It is a comparable broad CRO doing genetic characterization, release testing, and cell line QC for biologics developers, though at a much larger scale than Cergentis.
• Intertek Pharmaceutical Services: Intertek provides pharmaceutical contract lab services including CMC, biologics characterization, and release testing. Comparable to Cergentis as a high-quality analytical partner for drug developers, with a global footprint and broader service catalog.
• Charles River Laboratories: Charles River offers a Biologics Testing Services portfolio including cell line characterization, lot release, and biosafety testing for advanced therapies. It is a directly comparable CRO for biopharma QC, with a broader discovery and CDMO footprint.
• SGS Life Sciences: SGS is a global TIC (testing, inspection, certification) group with a dedicated Life Sciences division providing analytical and bioanalytical services to pharma customers, including biologics characterization and QC testing. It is a broad incumbent with overlapping biopharma analytical services.

Direct peers

• WuXi Advanced Therapies Unit: WuXi AppTec's Advanced Therapies unit provides testing, characterization, and manufacturing for cell and gene therapies. It competes with Cergentis in CGT-focused genetic QC and release testing, particularly for U.S.-based biotech sponsors.
• Lonza Cell & Gene Technologies: Lonza is a leading CDMO with analytics, cell & gene therapy manufacturing, and extensive testing services. Its bioanalytics and CGT testing platform overlaps directly with Cergentis' offering, while Lonza adds manufacturing scale that Cergentis does not.
• Catalent (Novo Holdings): Catalent provides cell and gene therapy development, analytical services, and manufacturing. Its Cell & Gene Therapy analytical services overlap with Cergentis' genetic characterization and QC for cell lines and advanced therapies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/solvias-ag
• Xx.com/Cergentis

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cergentis